Huakang Biomedical Holdings Company Limited (8622.HK)
HKD 0.18
(1.67%)
HKD 0.18
(1.67%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 16.09 Million CNY | 6.12% |
| 2022 | 21.27 Million CNY | 5.13% |
| 2021 | 20.23 Million CNY | -10.33% |
| 2020 | 22.56 Million CNY | 24.51% |
| 2019 | 18.12 Million CNY | -4.47% |
| 2018 | 18.97 Million CNY | -0.96% |
| 2017 | 19.15 Million CNY | 198.46% |
| 2016 | 6.41 Million CNY | 25.87% |
| 2015 | 5.09 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.27 Million CNY | -35.67% |
| 2024 Q2 | 5.27 Million CNY | 0.0% |
| 2023 Q2 | 5.25 Million CNY | 19.78% |
| 2023 Q4 | 8.2 Million CNY | 64.56% |
| 2023 Q1 | 4.38 Million CNY | -41.03% |
| 2023 Q3 | 4.98 Million CNY | -5.03% |
| 2023 FY | 22.57 Million CNY | 6.12% |
| 2022 Q2 | 4.66 Million CNY | 3.28% |
| 2022 Q1 | 4.51 Million CNY | -35.65% |
| 2022 FY | 21.27 Million CNY | 5.13% |
| 2022 Q3 | 4.85 Million CNY | 4.27% |
| 2022 Q4 | 7.43 Million CNY | 52.97% |
| 2021 Q4 | 7.01 Million CNY | 76.18% |
| 2021 FY | 20.23 Million CNY | -10.33% |
| 2021 Q3 | 3.98 Million CNY | -12.95% |
| 2021 Q2 | 4.57 Million CNY | -2.14% |
| 2021 Q1 | 4.67 Million CNY | -35.56% |
| 2020 Q4 | 7.25 Million CNY | 67.51% |
| 2020 Q3 | 4.32 Million CNY | -37.38% |
| 2020 Q2 | 6.91 Million CNY | 69.47% |
| 2020 Q1 | 4.07 Million CNY | -32.71% |
| 2020 FY | 22.56 Million CNY | 24.51% |
| 2019 Q4 | 6.06 Million CNY | 56.87% |
| 2019 Q3 | 3.86 Million CNY | -13.68% |
| 2019 Q2 | 4.47 Million CNY | 19.75% |
| 2019 FY | 18.12 Million CNY | -4.47% |
| 2019 Q1 | 3.73 Million CNY | -53.1% |
| 2018 Q3 | 3.49 Million CNY | -0.68% |
| 2018 Q4 | 7.96 Million CNY | 127.92% |
| 2018 FY | 18.97 Million CNY | -0.96% |
| 2018 Q2 | 3.52 Million CNY | -11.98% |
| 2018 Q1 | 3.99 Million CNY | 0.0% |
| 2017 FY | 19.15 Million CNY | 198.46% |
| 2016 FY | 6.41 Million CNY | 25.87% |
| 2015 FY | 5.09 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | 34.11% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 99.583% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | 54.702% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | 95.453% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | 5.9% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 97.277% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 98.691% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 96.804% |
| PuraPharm Corporation Limited | 216.62 Million HKD | 92.571% |
| SSY Group Limited | 1.98 Billion HKD | 99.188% |
| JBM (Healthcare) Limited | 163.87 Million HKD | 90.18% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | 94.399% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 99.945% |